Swine flu patients benefited from taking Tamiflu, says study

Sep 29, 2010

Healthy people who caught swine flu during the 2009 pandemic may have been protected against developing radiographically (x-ray) confirmed pneumonia by taking the antiviral drug oseltamivir (Tamiflu), concludes a study of cases in China published in the British Medical Journal today.

The researchers also show that oseltamivir treatment was associated with shorter duration of fever and viral RNA shedding (the period when a virus is contagious), although they stress that their findings should be interpreted with caution.

In 2009, A (H1N1) virus spread rapidly, resulting in millions of cases and over 18,000 deaths in over 200 countries.

Trials carried out on seasonal flu viruses have shown that taking antiviral drugs within 48 hours of symptom onset can reduce the severity and duration of symptoms, and possibly the risk of complications.

However, the extent to which antivirals may benefit otherwise healthy individuals with mild 2009 H1N1 infection, remains unknown.

So researchers reviewed the medical records of 1,291 patients in China with laboratory confirmed mild H1N1 infection during the 2009 pandemic.

The average age of patients was 20 years. Three quarters (76%) were treated with oseltamivir from a median of the third day of symptoms. Of 920 patients who had a chest x-ray, a minority (12%) had abnormal findings consistent with pneumonia.

No patients required admission or mechanical ventilation.

Using statistical modelling of the patients' data, the researchers ruled out the effects of age, sex, influenza vaccination, and treatment with antibiotics on the main study outcomes: getting pneumonia, having prolonged high fever, and viral RNA shedding. Oseltamivir treatment was then identified as a significant protective factor against subsequent development of pneumonia, confirmed by a chest x-ray. This protective effect was seen in all patients including those who started treatment more than two days after onset of symptoms.

Oseltamivir treatment started within two days of symptom onset also reduced the duration of fever and viral RNA shedding, they add. They also found that 2009 H1N1 might be shed longer than seasonal influenza virus.

These findings are consistent with patients with the 2009 H1N1 benefiting from use of oseltamivir, conclude the authors. However, they stress that their finding that treatment protected against subsequent radiographic pneumonia should be interpreted with caution, given the retrospective design of this work and the fact that not all patients underwent a chest x-ray.

They call for continued investigation into the effectiveness of antiviral treatment "to allow for improvement both in clinical treatment and public health guidance."

Explore further: Doctors' checklist could help decrease length of COPD patients' hospital stay

Related Stories

Drug-resistant swine flu cluster on Vietnam train

Dec 09, 2009

(PhysOrg.com) -- A cluster of seven people infected with a Tamiflu-resistant strain of pandemic H1N1 influenza has been identified in Vietnam by a team including Oxford researchers.

H1N1 influenza hits older children

May 04, 2010

Children hospitalized with pandemic H1N1 influenza in 2009 were older and more likely to have underlying medical conditions than children hospitalized with seasonal influenza during prior flu seasons, according to a study ...

Recommended for you

Score IDs patients with upper extremity DVT at low risk

9 hours ago

(HealthDay)—For patients with upper-extremity deep vein thrombosis (DVT), six easily available factors can be used to create a score that identifies those at low risk of adverse events during the first ...

Combined drug treatment combats kidney disease

20 hours ago

A recent discovery by drug researchers whereby coupling specific cell membrane receptors has altered kidney cell function has triggered a re-think of how to treat chronic kidney disease (CKD) more effectively.

Active substance targeting dreaded hospital germs

20 hours ago

In the German Center for Infection Research (DZIF), scientists have conducted clinical studies on an active substance against the dreaded hospital pathogen Staphylococcus aureus: a highly effective protein from bacteriophages ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.